Efficacy of Povidone-Iodine Nasal and Oral Antiseptic Preparations Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2)
Pelletier et al.
, Efficacy of Povidone-Iodine Nasal and Oral Antiseptic Preparations Against Severe Acute Respiratory..
, Ear, Nose & Throat Journal, doi:10.1177/0145561320957237 (In Vitro)
Pelletier et al., 21 Sep 2020, peer-reviewed, 6 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
Abstract: Basic Science Study: Trends in Practice & Training
Efficacy of Povidone-Iodine Nasal and Oral
Antiseptic Preparations Against Severe
Acute Respiratory Syndrome-Coronavirus
Ear, Nose & Throat Journal
2021, Vol. 100(2S) 192S–196S
ª The Author(s) 2020
Article reuse guidelines:
Jesse S. Pelletier, MD1, Belachew Tessema, MD, FACS2,3 ,
Samantha Frank, MD3 , Jonna B. Westover4, Seth M. Brown, MD2,3,
and Joseph A. Capriotti, MD5
Introduction: Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the global
pandemic of coronavirus disease 2019 (COVID-19). From the first reported cases in December 2019, the virus has spread to over
4 million people worldwide. Human-to-human transmission occurs mainly through the aerosolization of respiratory droplets.
Transmission also occurs through contact with contaminated surfaces and other fomites. Improved antisepsis of human and
nonhuman surfaces has been identified as a key feature of transmission reduction. There are no previous studies of povidone
iodine (PVP-I) against SARS-CoV-2. This study evaluated nasal and oral antiseptic formulations of PVP-I for virucidal activity against
SARS-CoV-2. This is the first report on the efficacy of PVP-I against the virus that causes COVID-19. Methods: Povidone iodine
nasal antiseptic formulations and PVP-I oral rinse antiseptic formulations from 1% to 5% concentrations as well as controls were
studied for virucidal efficacy against the SARS-CoV-2. Test compounds were evaluated for ability to inactivate SARS-CoV-2 as
measured in a virucidal assay. SARS-CoV-2 was exposed directly to the test compound for 60 seconds, compounds were then
neutralized, and surviving virus was quantified. Results: All concentrations of nasal antiseptics and oral rinse antiseptics evaluated
completely inactivated the SARS-CoV-2. Conclusions: Nasal and oral PVP-I antiseptic solutions are effective at inactivating the
SARS-CoV-2 at a variety of concentrations after 60-second exposure times. The formulations tested may help to reduce the
transmission of SARS-CoV-2 if used for nasal decontamination, oral decontamination, or surface decontamination in known or
suspected cases of COVID-19.
povidone iodine, SARS-CoV-2, nasal rinse, oral rinse
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.